Table 1 Characteristics of patients and their DTs
|  | Entire DT cohort (N = 35) | DTs with added benefit of PWI over WA-PVI (N = 8) | DTs where added PWI was not beneficial (N = 27) | P value | DTs where WA-PVI was more beneficial than IO-PVI (N = 6) | DTs where WA-PVI was not more beneficial than IO-PVI (N = 21) | P value |
|---|---|---|---|---|---|---|---|
Clinical information | |||||||
 Male | 27 (77) | 5 (63) | 22 (82) | 0.346 | 6 (100) | 16 (76) | 0.555 |
 Age, Y | 66 [59–73] | 72 [63–76] | 63 [58–70] | 0.169 | 62 [47–68] | 63 [59–71] | 0.335 |
 Body Mass Index, kg/m2 | 30.6 ± 4.6 | 29.3 ± 3.4 | 31.0 ± 4.9 | 0.355 | 31.8 ± 5.8 | 30.8 ± 4.8 | 0.692 |
 CHA2DS2-VASc score | 2 [1–3] | 3 [1–4] | 2 [1–3] | 0.412 | 2 [0–3] | 2 [1–3] | 0.655 |
 Left ventricular ejection fraction, % | 54.7 ± 8.7 | 56.9 ± 11.5 | 54.1 ± 7.8 | 0.437 | 54.5 ± 11.1 | 54.0 ± 7.0 | 0.893 |
 History of previous PVI | 12 (34) | 1 (13) | 11 (41) | 0.216 | 4 (67) | 7 (33) | 0.187 |
 Days from MRI to ablation, days | 19 [14–23] | ·· | ·· | ·· | ·· | ·· | ·· |
Global LA information | |||||||
 LA volume, ml | 132 [113–173] | 116 [102–135] | 140 [117–176] | 0.132 | 138 [122–145] | 140 [115–181] | 0.977 |
 FF in the LA, % | 16 ± 6 | 19 ± 6 | 15 ± 6 | 0.091 | 21 ± 7 | 13 ± 5 | 0.004* |
 The number of LA-LRs | 3 [2–4] | 5 [3–5] | 3 [2–4] | 0.019* | 4 [3,4] | 2 [2,3] | 0.018* |
Local substrate features | |||||||
 LAPW volume, cm3 | 2.94 ± 0.85 | 2.78 ± 0.83 | 2.99 ± 0.86 | 0.551 | ·· | ·· | ·· |
 FF within LAPW, % | 9 [6–16] | 21 [10–28] | 8 [4–13] | 0.009* | ·· | ·· | ·· |
 Proportion of high FE locations within LAPW, % | 50 ± 23 | 66 ± 13 | 45 ± 24 | 0.028* | ·· | ·· | ·· |
 ≥ 10% LVA at LAPW | 4 (12) | 1 (13) | 3 (12) | 1.000 | ·· | ·· | ·· |
 PV antrums volume, cm3 | 2.66 ± 1.19 | ·· | ·· | ·· | 2.66 ± 1.92 | 2.71 ± 1.08 | 0.935 |
 FF within PV antrums, % | 20 [11–26] | ·· | ·· | ·· | 28 [18–50] | 17 [10–21] | 0.157 |
 Proportion of high FE locations within PV antrums, % | 51 ± 16 | ·· | ·· | ·· | 51 ± 19 | 48 ± 15 | 0.659 |